FDA clears radiology AI triage tool to check for 10 additional findings on CT scans
a2z Radiology's Abdo-Triage software just got FDA approval to detect 10 additional conditions on abdominal CT scans, bringing its total flagged findings to 17. The tool helps radiologists prioritize which scans need immediate review by highlighting suspected abnormalities.
- The newly cleared findings include obstructing kidney stones, appendicitis, traumatic injuries to the spleen and liver, and various types of bleeding or fluid buildup in the abdomen
- Abdo-Triage analyzes CT scans in adults 22+ and works alongside radiologist interpretation, not as a replacement—doctors still make final clinical judgments
- This is a2z's second FDA clearance; the Boston startup raised $5 million last year and has Breakthrough Device designation, which speeds up regulatory review
The FDA has cleared a2z Radiology's Abdo-Triage software to detect 10 additional findings on abdominal-pelvic CT scans, bringing its total detection range to 17 conditions. The Boston-based startup, founded in 2024, received this second FDA clearance after an initial approval in late 2025. The newly cleared findings include obstructing ureteral stones, hydroureter, retroperitoneal hematoma, large volume ascites, acute appendicitis, intra-abdominopelvic abscess, hemoperitoneum or complex free fluid, and three types of traumatic injury (splenic, hepatic, and renal). The tool analyzes CT scans with or without contrast in adults 22 and older, flagging suspected positive cases to help radiologists prioritize studies for review.
The software works alongside radiologist interpretation rather than replacing it—doctors still review full scans and make their own clinical judgments. Co-founder and CEO Samir Rajpurkar framed the expansion as part of the company's broader mission to create an "intelligence layer for medical imaging" that supports care teams across the range of cases they encounter. The product also holds FDA Breakthrough Device designation, which accelerates approval pathways for innovations addressing unmet clinical needs.
A2z Radiology raised $5 million in investor funding last year, coinciding with its first FDA clearance. The company's leadership includes Pranav Rajpurkar, PhD, who has published research on the need for generalist AI models in radiology that go beyond single-task applications. This expansion signals growing momentum in the radiology AI space, where multiple startups are now pursuing FDA clearances for imaging analysis tools.